AstraZeneca PLC

Discover how AstraZeneca’s efzimfotase alfa achieved breakthrough pediatric results in phase‑III trials for hypophosphatasia, its market‑access strategy, and future growth potential.

Explore how the Taltz + Zepbound combo boosts Psoriatic Arthritis outcomes and drives higher payer value with dual‑indication strategy and outcome‑based reimbursement.

Explore how AstraZeneca’s €260bn market cap and groundbreaking therapeutics, from Tagraxofusp to PulmoVax, shape FTSE 100 dynamics and healthcare budgets.

Explore how AstraZeneca’s Koselugo approval and German vaccine liability case shape its rare‑disease strategy and financial outlook.

Explore how AstraZeneca’s Q4 2025 earnings reveal a sharp rise in profit driven by oncology sales, a £3.5 bn pipeline push, and a 12 % dividend hike, setting a cautious 2026 outlook amid patent and regulatory challenges.

Explore how AstraZeneca’s earnings, R&D pipeline, and market‑access strategies shape its valuation and future growth potential.

Explore why AstraZeneca’s future is both bullish and cautious after its Nasdaq‑100 exit, and how index rebalancing, pharma fundamentals, and macro trends shape investor outlook.

Stable AstraZeneca PLC shares, a diversified therapeutic pipeline, and proactive regulatory strategy signal continued confidence and growth prospects for investors.

Read how AstraZeneca’s latest update shows a mix of oncology setbacks, a breakthrough therapy win for Enhertu, and a strategic exit from Andexxa, illustrating the company’s dynamic portfolio strategy and regulatory moves.

Read how AstraZeneca’s oncology mix—lung‑cancer setback vs. breast‑cancer breakthrough and safety‑driven product pull—shows its strategic resilience.